$NBIO ~ "Because EDV is found in a variety of cancers, our clinical trials involving PTB could have implications for a broad range of more common cancers, such as breast, colon and lung," noted Nascent CEO, Sean Carrick. "The current Phase 1 trial has been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors." https://finance.yahoo.com/news/nascent-biotec...00666.html